Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| ranibizumab | Ranibizumab is a monoclonal antibody fragment (Fab) which could inhibit angiogenesis via suppressing vascular endothelial growth factor (VEGF) A. In Dec. 2016, it was approved for the treatment of the age-related macular degeneration (AMD) and visual impairment caused by choroidal neovascularization (CNV). Synonyms: RG-6321; Lucentis; Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1 chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain. Grades: ≥95%. CAS No. 347396-82-1. Molecular formula: C2158H3282N562O681S12. Mole weight: 48350. |  |
| Ranibizumab | antiangiogenic monoclonal antibody macular degeneration therapy. CAS No. 347396-82-1. Product ID: 1-01609. Molecular formula: C2158H3282N562O681S12. Mole weight: 48 kDA. |  |
| Ranibizumab (anti-VEGF) | Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) [1]. Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: RG-6321 (anti-VEGF). CAS No. 347396-82-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9951A. |  |
| Faricimab | Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 ( Ang-2 ) and vascular endothelial growth factor-A ( VEGF-A ). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) [1] [2] [3] [4] [5]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: RG7716. CAS No. 1607793-29-2. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99116. | |
Our database is helping our users find suppliers everyday.
